Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $18.34, for a total transaction of $144,189.08. Following the completion of the sale, the director now owns 31,978 shares of the company’s stock, valued at approximately $586,476.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Amphastar Pharmaceuticals, Inc. (AMPH) traded up $0.14 during mid-day trading on Friday, hitting $18.46. 108,118 shares of the stock were exchanged, compared to its average volume of 291,514. Amphastar Pharmaceuticals, Inc. has a 52 week low of $12.05 and a 52 week high of $21.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08. The firm has a market cap of $842.73, a P/E ratio of 122.20 and a beta of 1.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The company had revenue of $57.90 million during the quarter, compared to the consensus estimate of $57.23 million. During the same period last year, the firm earned $0.14 EPS. The company’s revenue for the quarter was down 9.8% on a year-over-year basis. equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post -0.03 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its position in shares of Amphastar Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after acquiring an additional 842 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $111,000. State of Alaska Department of Revenue lifted its position in shares of Amphastar Pharmaceuticals by 77.2% during the 2nd quarter. State of Alaska Department of Revenue now owns 7,052 shares of the company’s stock valued at $125,000 after acquiring an additional 3,072 shares during the period. Municipal Employees Retirement System of Michigan lifted its position in shares of Amphastar Pharmaceuticals by 2.8% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock valued at $151,000 after acquiring an additional 230 shares during the period. Finally, BNP Paribas Arbitrage SA lifted its position in shares of Amphastar Pharmaceuticals by 58.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 10,545 shares of the company’s stock valued at $188,000 after acquiring an additional 3,880 shares during the period. Institutional investors own 44.14% of the company’s stock.

A number of equities research analysts recently commented on the stock. Needham & Company LLC raised their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, December 1st. BMO Capital Markets raised their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a research report on Friday, November 10th. Raymond James Financial downgraded shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective for the company. in a research report on Thursday, November 9th. Jefferies Group set a $19.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 29th. Finally, Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus target price of $20.86.

TRADEMARK VIOLATION NOTICE: “Amphastar Pharmaceuticals, Inc. (AMPH) Director Stephen B. Shohet Sells 7,862 Shares” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/12/08/amphastar-pharmaceuticals-inc-amph-director-stephen-b-shohet-sells-7862-shares.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.